Kimberly M Thompson Selected Research

Poliomyelitis (Polio)

10/2022	Polio by the Numbers-A Global Perspective.
5/2021	Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
4/2021	The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
1/2021	Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
1/2021	A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
1/2021	Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
1/2021	Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
1/2021	Potential Future Use, Costs, and Value of Poliovirus Vaccines.
1/2021	Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
1/2021	An Updated Economic Analysis of the Global Polio Eradication Initiative.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kimberly M Thompson Research Topics

Disease

47	Poliomyelitis (Polio) 10/2022 - 12/2006
10	Measles 01/2017 - 07/2012
9	Rubella (German Measles) 01/2017 - 07/2012
7	Infections 01/2016 - 04/2013
3	COVID-19 11/2021 - 01/2021
2	Vaccine-Preventable Diseases 01/2016 - 06/2010
2	Reinfection 01/2016 - 04/2013
1	Wounds and Injuries (Trauma) 01/2020
1	Shoulder Injuries 01/2020
1	Communicable Diseases (Infectious Diseases) 01/2018
1	Mumps 01/2017
1	Congenital Rubella Syndrome (Syndrome, Congenital Rubella) 01/2016
1	Primary Immunodeficiency Diseases 09/2015
1	Drowning 03/2003
1	Whooping Cough (Pertussis) 12/2002

Drug/Important Bio-Agent (IBA)

51	VaccinesIBA 10/2022 - 12/2002
27	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 11/2021 - 12/2006
11	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2021 - 12/2006
6	Poliovirus VaccinesIBA 01/2021 - 12/2006
3	Rubella VaccineIBA 01/2017 - 01/2016
2	Measles VaccineIBA 01/2016 - 01/2016
2	AntibodiesIBA 01/2016 - 01/2016
1	Hepatitis B e AntigensIBA 01/2017
1	Cholera Vaccines FDA Link 01/2016
1	AntigensIBA 01/2016
1	Pharmaceutical PreparationsIBA 09/2015
1	Antiviral Agents (Antivirals)IBA 09/2015
1	Vitamin A (Retinol)FDA LinkGeneric 12/2010
1	Hazardous Substances (Hazardous Materials)IBA 12/2006
1	neodymium pyrocatechin disulfonate (NPD)IBA 03/2003

Therapy/Procedure

1	Protective Devices (Safety Device) 03/2003